Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Preferred Shares (2016 - 2025)

Historic Preferred Shares for CorMedix (CRMD) over the last 12 years, with Q3 2025 value amounting to $92.0.

  • CorMedix's Preferred Shares fell 4945.05% to $92.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $92.0, marking a year-over-year decrease of 4945.05%. This contributed to the annual value of $137.0 for FY2024, which is N/A changed from last year.
  • CorMedix's Preferred Shares amounted to $92.0 in Q3 2025, which was down 4945.05% from $92.0 recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Preferred Shares peaked at $182.0 during Q1 2021, and registered a low of $92.0 during Q1 2025.
  • Over the past 5 years, CorMedix's median Preferred Shares value was $182.0 (recorded in 2021), while the average stood at $164.5.
  • As far as peak fluctuations go, CorMedix's Preferred Shares changed by 0.0% in 2022, and later tumbled by 4945.05% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Preferred Shares stood at $182.0 in 2021, then changed by 0.0% to $182.0 in 2022, then changed by 0.0% to $182.0 in 2023, then dropped by 24.73% to $137.0 in 2024, then tumbled by 32.85% to $92.0 in 2025.
  • Its Preferred Shares stands at $92.0 for Q3 2025, versus $92.0 for Q2 2025 and $92.0 for Q1 2025.